AMAG Pharmaceuticals Announces New Management Appointments
April 01 2015 - 3:00PM
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new
management appointments which expand the company's ability to
engage with external partners and stakeholders. Linda Lennox has
joined the company as vice president of investor relations &
corporate communications, assuming responsibilities from Kathryn
Carr Payne who has been promoted to vice president of external
affairs. In this newly established role for AMAG, Ms. Payne will
direct the company's public affairs activities, which includes
leading AMAG's public relations, policy and advocacy initiatives at
the state and national level.
"Following the Lumara Health transaction, we made the strategic
decision to create a new executive function within AMAG responsible
for managing the company's external relations, including our
engagement with policymakers, non-profit advocacy organizations and
patients, to advance areas of mutual interest, such as expanding
patient access to therapies," said William Heiden, president and
chief executive officer. "I am confident that Katie's and Linda's
complementary skill sets will help advance our business and policy
objectives, while ensuring alignment with our overall corporate
vision, values and patient-centric focus."
Ms. Payne joined AMAG in May 2014 from APCO Worldwide, a global
public affairs and strategic communications firm based in
Washington, D.C., where she led communications, policymaker
outreach and brand-building programs designed to position
healthcare companies, their products, issues and leadership to
external audiences, including media, investors, customers and
patients. Ms. Payne holds a bachelor's degree in writing and
business management and a master's degree in communications from
The Johns Hopkins University.
Ms. Lennox has 25 years of leadership experience with companies
in the healthcare and energy sectors. Prior to joining AMAG, Ms.
Lennox served as senior director, investor relations &
corporate communications at Lantheus Medical Imaging, Inc., a
privately held global diagnostic imaging company. Prior to that,
Ms. Lennox served as vice president, investor & media relations
at Critical Therapeutics, a publicly traded biotechnology/specialty
pharmaceutical company. Prior to joining Critical Therapeutics, Ms.
Lennox spent 15 years in positions of increasing responsibility at
two separate publicly traded energy companies. Ms. Lennox started
her career at Putnam Investments and Smith Barney, where she
obtained her series 6, 7 and 63 licenses. She received a bachelor's
degree in economics from the University of Vermont.
Inducement Equity Awards
In connection with Ms. Lennox's entering into employment with
AMAG, Ms. Lennox will be granted (i) an option to purchase 9,500
shares of common stock and (ii) 2,500 restricted stock units. The
option will have an exercise price equal to the closing price of
AMAG's common stock on the grant date and will be exercisable in
four equal annual installments beginning on the first anniversary
of the grant date. The option will have a ten-year term and be
subject to the terms and conditions of the stock option agreement
pursuant to which the option will be granted. The restricted stock
units will vest in three equal annual installments beginning on the
first anniversary of the grant date and will be subject to the
restricted stock unit agreement pursuant to which the restricted
stock units will be granted. These equity awards will be granted
without stockholder approval as inducements material to Ms. Lennox
entering into employment with AMAG in accordance with NASDAQ
Listing Rule 5635(c)(4).
About AMAG
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company
with a focus on maternal health, anemia and cancer supportive
care. The primary goal of AMAG is to bring to market therapies
that provide clear benefits and improve patients' lives. In
addition to continuing to pursue opportunities to make new
advancements in patients' health and to enhance treatment
accessibility, AMAG intends to continue to expand and diversify its
portfolio through the in-license or purchase of additional
pharmaceutical products or companies.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws. Any statements contained herein
which do not describe historical facts, including but not limited
to statements regarding: Ms. Lennox's contributions and
responsibilities are forward-looking statements which involve risks
and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking
statements.
Such risks and uncertainties include, among others, our ability
to attract and retain key employees, and the resulting disruptions
to our operations if we fail to do so and such other risks
identified in our Securities and Exchange Commission (SEC) filings,
including our Annual Report on Form 10-K for the year ended
December 31, 2014 and subsequent filings with the SEC. We caution
you not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made.
We disclaim any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG
Pharmaceuticals, Inc. Lumara Health™ is a trademark of Lumara
Health Inc.
CONTACT: AMAG Pharmaceuticals, Inc. Contact:
Maryann Cimino, 617-498-3375
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Apr 2024 to May 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From May 2023 to May 2024